Literature DB >> 7855320

Erythropoietin production in patients with chronic renal failure.

A Kato1, A Hishida, H Kumagai, R Furuya, T Nakajima, N Honda.   

Abstract

Studies were performed to reexamine the response of erythropoietin (Epo) production to acute hypoxic stimuli in patients with end-stage renal disease (ESRD). In the absence of acute bleeding or hypoxia, the serum Epo level in ESRD was similar to that of normal subjects despite severe anemia. In 11 dialysis patients with acute bleeding, the decrease in the Hb level from 8.9 to 5.8 g/dL provoked a significant increase in serum Epo up to 52.2 times the normal value. The increase in serum Epo was associated with a significant increase in corrected reticulocyte. Systemic hypoxemia (PaO2 < 65 mm Hg) in 8 dialysis patients provoked a significant elevation in the serum Epo level up to 24.6 times the normal level. There was an inverse relationship between serum Epo and arterial PaO2 (r = -0.715). The serum Epo level in these patients declined to or near the normal value after recovery from acute hypoxic stress. These data suggest that the ability of the Epo production is well preserved in ESRD, indicating that acute hypoxic stimuli provoke a significant increase in serum Epo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855320     DOI: 10.3109/08860229409044892

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

2.  Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients.

Authors:  Jose A Calvo; Dana C Miskulin; Klemens B Meyer; Daniel E Weiner
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-22       Impact factor: 8.237

3.  The effect of altitude on dosing and response to erythropoietin in ESRD.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Jerry Avorn; Brian D Bradbury; Kenneth J Rothman; Michael Fischer; Jyotsna Mehta; Wolfgang C Winkelmayer
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

4.  Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.

Authors:  Ingo Flamme; Felix Oehme; Peter Ellinghaus; Mario Jeske; Jörg Keldenich; Uwe Thuss
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 5.  Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.

Authors:  Jing Liu; Qingqing Wei; Chunyuan Guo; Guie Dong; Yu Liu; Chengyuan Tang; Zheng Dong
Journal:  Int J Mol Sci       Date:  2017-04-30       Impact factor: 5.923

6.  Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.

Authors:  Robert Provenzano; James Tumlin; Raja Zabaneh; James Chou; Stefan Hemmerich; Thomas B Neff; K-H Peony Yu
Journal:  J Clin Pharmacol       Date:  2020-06-30       Impact factor: 3.126

7.  Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.

Authors:  Anatole Besarab; Robert Provenzano; Joachim Hertel; Raja Zabaneh; Stephen J Klaus; Tyson Lee; Robert Leong; Stefan Hemmerich; Kin-Hung Peony Yu; Thomas B Neff
Journal:  Nephrol Dial Transplant       Date:  2015-08-03       Impact factor: 5.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.